Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst… - … England Journal of …, 2018 - Mass Medical Soc
Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen… - New England Journal …, 2018 - hal.science
BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
JF Seymour, TJ Kipps, B Eichhorst… - The New England …, 2018 - europepmc.org
Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
[PDF][PDF] Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen… - N Engl J Med, 2018 - core.ac.uk
BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen… - N. Engl. J …, 2018 - kups.ub.uni-koeln.de
BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
[引用][C] Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst… - New England …, 2018 - produccioncientifica.ucm.es
BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst… - The New England …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst… - … England Journal of …, 2018 - eprints.whiterose.ac.uk
Background: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen… - New England Journal …, 2018 - cir.nii.ac.jp
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps… - New England …, 2018 - researchinformation.amsterdamumc …
BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …